WO2011101860A1 - Nicotine-containing soft gelatin pastilles - Google Patents
Nicotine-containing soft gelatin pastilles Download PDFInfo
- Publication number
- WO2011101860A1 WO2011101860A1 PCT/IN2010/000768 IN2010000768W WO2011101860A1 WO 2011101860 A1 WO2011101860 A1 WO 2011101860A1 IN 2010000768 W IN2010000768 W IN 2010000768W WO 2011101860 A1 WO2011101860 A1 WO 2011101860A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nicotine
- pastille
- mass
- group
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Definitions
- the present invention relates to pastilles.
- the present invention relates to soft pastilles for nicotine replacement therapy.
- a soft pastille means a resilient preparation which is can be retained and sucked in the mouth.
- Nicotine is an alkaloid found in the plants belonging to family Solanaceae. Nicotine is a hygroscopic, oily liquid which is miscible with water in its base form. Nicotine is optically active and has two enantiomeric forms. The naturally occurring form of nicotine is levorotatory. The dextrorotatory form ((+) nicotine) has only one-half the physiological activity of (-) nicotine. It is therefore weaker in the sense that a higher dose is required to attain the same effects. As nicotine enters the body, it is distributed quickly through the bloodstream and can cross the blood-brain barrier. On an average it takes about ten seconds for the substance to reach the brain when inhaled. The half life of nicotine in the body is around two hours.
- Nicotine is the main addictive ingredient in the tobacco used in cigarettes, cigars, snuff and other nicotine-containing products. It is generally known that active as well as passive smoking of tobacco products, such as cigarettes, cigars and pipe tobacco presents serious health risks to the user and those subjected to secondary smoke. It is also known
- nicotine cessation products and therapies are known. However, in most of the cases the mere replacement of cigarettes with another nicotine source may not be sufficient to ensure success in smoking cessation therapy.
- the available nicotine cessation products include lozenges, gums, transdermal patches and the like. Lozenges and chewing gums provide oral delivery of nicotine, whereas transdermal patch treatments deliver nicotine through the wearer's skin.
- Nicotine chewing gum containing nicotine polacrilex and transdermal nicotine are two of the more popular forms of nicotine replacement available commercially.
- Nicotine gum is actually an ion-exchange resin that releases nicotine slowly when the patient chews and the nicotine present in the mouth is delivered directly to the systemic circulation by buccal absorption. However, much of the nicotine is retained in the gum through incomplete chewing or is largely wasted through swallowing, so that the systemic bioavailability of nicotine from gum is low and averages only 30-40%.
- compositions containing nicotine disclose compositions containing nicotine.
- United States Patent No. 4967773 discloses a lozenge formed by compression of at least two mixed components, one of said components including lactose or a lactose containing substance and the other of said components comprising a carrier having nicotine or a nicotine derivative absorbed therein such that there is no direct contact between the nicotine and the lactose whilst together in the lozenge.
- GB2230439 discloses a lozenge which is a substitute for smoking tobacco comprises a lozenge core which contains nicotine and/or a nicotine substitute and a shell or coating around the lozenge core.
- GB2299756 discloses pastilles containing nicotine in an acacia gum or gelatine base.
- United States Patent No. 5488962 discloses chewing gum formed into 3g strips, characterized in that each strip contains not more than 25 wt. % of a gum base and from 0.3-0.4 mg of nicotine dispersed in the gum base.
- United States Patent No. 6183775 discloses a controlled release lozenge consisting of (a) 50 to 99 % of a soluble filler; (b) 0.5 to 30 % of an insoluble film forming agent which is selected from the group consisting of a polyacrylate, ethyl cellulose and mixtures thereof; (c) 0.5 to 30 % of a swellable polymer which is selected from the group consisting of xanthan gum, guar gum, cellulose derivatives and mixtures thereof; and (d) nicotine or a salt or derivative of nicotine.
- -Uftited-States- ateiit No. 6 8073 ⁇ 4i aiscloses a nicotine lozenge consisting of nicotine, mannitol, xylitol, mint flavor, ammonium glycyrrhizinate, sodium carbonate, sodium bicarbonate, hydrogenated vegetable oil and magnesium stearate.
- United States Patent No. 6344222 discloses a chewing gum composition for systemic, oral administration of nicotine constituent, said composition comprising a) a nicotine constituent; b) a gum base matrix, said gum base matrix including at least one hydrophilic polymer and at least one hydrophobic polymer; and c) a buffer.
- US2004151771 discloses a flavored a lozenge comprising a sustained release wet matrix of ethylcellulose and a flavoring agent selected from essential oils, constituents of essential oils, and mixtures thereof, wherein, in an aqueous environment, the matrix gradually releases the flavoring agent over a time period of at least 45 minutes.
- the active ingredient used is nicotine
- US2005034738 discloses a chewing tobacco substitute comprising a non-tobacco leaflike material; an alkaline chemical; and a nicotine compound capable of being absorbed orally.
- the nicotine compound used is nicotine polacrilex.
- US2005002993 discloses a confectionery product for delivering at least one pharmaceutically active agent [such as nicotine replacement agents] which includes a hard outer shell and a core comprised of a core material which is or forms a liquid-like to a gel-like substance in the oral cavity and is capable of delivering pharmaceutically active agents to infected and/or irritated tissues of the throat.
- a pharmaceutically active agent such as nicotine replacement agents
- US2005123502 discloses an oral composition comprising a nicotine active, a polycarbophil component or a salt thereof and an alginic acid component or a salt thereof.
- US20050053665 discloses a nicotine-containing pharmaceutical composition
- a nicotine-containing pharmaceutical composition comprising nicotine and cellulose of non-seed organism origin.
- Said composition can be in the form of chewing gum, mouth spray, buccal sachet, lozenge or a tablet.
- US2007269492 discloses-a-X-oated or-a4-desa ⁇ e- ⁇ fms- ⁇ r- i delivery ⁇ nicotine in any form to a subject by rapid intraoral delivery of nicotine comprising at least one core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one additive.
- US2007269386 discloses a buffered pharmaceutical oral formulation comprising nicotine, characterized in that it is buffered with at least trometamol.
- the formulation can be in the form of a mouth spray, a capsule, a chewing gum, a chewable tablet, a tablet, a melt tablet and a lozenge.
- an oral lozenge composition comprising: a) a master granule component comprising: at least one an alkaline buffering agent; at least one dissolution modifier; and at least one filler; b) a nicotine polacrilex; and c) at least one alkaline buffering agent.
- the dissolution modifier used is selected from the group consisting of xanthan gum, acacia, carbomer, carboxymethylcellulose, carrageenan and cellulose.
- US20100004294 discloses a lozenge composition for achievement of a fast onset of action of nicotine after application of the solid dosage form to the oral cavity of a subject, comprising a nicotine-cellulose combination and one or more pharmaceutically acceptable excipients.
- Nicotine containing products in the form of chewing gums are associated with problems such as disposal problem and chewing is very often socially unacceptable.
- chewing of chewing gum leads to breaking of polymer coating and result in excessive release of nicotine in buccal cavity which in turn causes nausea, bad taste and burning sensation.
- Nicotine containing lozenges also possess disadvantages such as person using such lozenges is not comfortable to keep a hard product in the buccal cavity for prolong period. Another disadvantage is that lozenges get break down into pieces followed by accidental swallowing which in turn result in excessive transfer of nicotine in GI tract and causes nausea and burning sensation.
- a palatable nicotine containing formulation which is devoid of gums and which releases the nicotine for prolong period of time in controlled manner without causing nausea, bad taste and burning sensation.
- a soft pastille comprising: a. nicotine active in an amount of about 0.05% to about 1% of the mass of the pastille;
- gelling agent in an amount of about 5 % to about 40 % of the mass of the pastille
- plasticizer in an amount of about 30 % to about 70 % of the mass of the pastille
- sweetener in an amount of about 0.05 % to about 10% of the mass of the pastille
- releasing agent in an amount of about 0.5% to about 30 % of the mass of the pastille
- preservative in an amount of about 0.05% to about 2% of the mass of the pastille
- flavouring agent in an amount of about 0.01% to 5% of the mass of the pastille
- the nicotine active is selected from the group consisting of nicotine polacrilex, tobacco plant extract containing nicotine, derivatives of nicotine, nicotine oil, nicotine salts, nicotine cation exchanger, nicotine inclusion complex, nicotine bound to cellulose or starch micro-spheres, metabolites of nicotine and combination thereof.
- the nicotine active is nicotine polacrilex or tobacco plant extract containing nicotine.
- the gelling agent is selected from the group consisting of gelatin, and carrageenan.
- the gelling agent is gelatin.
- the ratio of gelling agent to plasticizer is in the range of about 1 :2.7 to about 1:3.
- the plasticizer is selected from the group consisting of glycerine and sorbitol.
- the plasticizer is glycerine
- the releasing agent is selected from the group consisting of lecithin, oil and starch.
- the releasing agent is lecithin.
- the sweetener is at least one selected from the group consisting of stevia, aspartame, saccharin, sucralose, sucrose, dextrose and lactose.
- the preservative is at least one selected from the group consisting of methyl paraben, propyl paraben, sodium methyl paraben and sodium propyl paraben.
- the flavouring agent is selected from the group consisting of menthol, vanillin, peppermint, lemon, mint, strawberry, banana, pineapple, orange and raspberry.
- a soft pastille comprising: a. nicotine active in an amount of about 0.05% to about 1% of the mass of the pastille; b. gelling agent in an amount of about 5 % to about 40 % of the mass of the pastille;
- plasticizer in an amount of about 30 % to about 70 % of the mass of the pastille
- sweetener in an amount of about 0.05 % to about 10 % of the mass of the pastille
- releasing agent in an amount of about 0.5% to about 30 % of the mass of the pastille
- preservative in an amount of about 0.05% to about 2% of the mass of the pastille
- flavouring agent in an amount of about 0.01% to 5% of the mass of the pastille
- the nicotine active is selected from the group consisting of nicotine polacrilex, tobacco plant extract containing nicotine, derivatives of nicotine, nicotine oil, nicotine salts, nicotine cation exchanger, nicotine inclusion complex, nicotine bound to cellulose or starch micro-spheres, metabolites of nicotine and combination thereof.
- the nicotine active is nicotine polacrilex.
- the nicotine active is tobacco plant extract containing nicotine.
- the gelling agent used for the preparation of soft pastille in accordance with the present invention is selected from the group consisting of gelatin and carrageenan.
- gelatin is used as a gelling agent as the gel obtained from gelatin is thermo-reversible. Because of thermo- reversible property, after cooling the gelatin solution the viscosity increases progressively and passes from a sol to a gel. On the other hand, if the gel is heated, it dissolves and once again becomes a solution.
- the plasticizer is selected from the group consisting of glycerine and sorbitol.
- the plasticizer used is glycerine.
- the critical parameter in the preparation of soft pastille in accordance with the present invention is the ratio of gelling agent to plasticizer. It is found that when the ratio of gelling agent to glycerin is kept below 1 :2.7, the formed mixture becomes hard and gets stuck in the nozzle while transferring it into the die cavities in order to form pastilles. It is also found that when the ratio of gelling agent to glycerin is kept above 1 :3, the formed mixture becomes less viscous and results in formation of poor quality pastilles.
- the ratio of gelling agent to glycerin for the preparation of soft pastilles containing nicotine is kept in the range of about 1 :2.7 to aboutl :3.
- the releasing agent is selected from the group consisting of lecithin, oil and starch.
- the sweetener used in the preparation of pastilles in accordance with the present invention is at least one selected from the group consisting of stevia, aspartame, saccharin, sucralose, sucrose, dextrose and lactose.
- the preservative is at least one selected from the group consisting of methyl paraben, propyl paraben, sodium methyl paraben and sodium propyl paraben.
- flavouring agent employed in the preparation of pastilles of the present invention is selected from the group consisting of menthol, vanillin, peppermint, lemon, mint, strawberry, banana, pineapple, orange and raspberry.
- First step is introducing accurately weighed glycerine and water in a reactor. To this accurately weighed gelatin and lecithin are added to form a first mixture.
- Nicotine active is added and the resulted mixture is mixed for about 30 to about 45 minutes at 1500 rpm to form a second mixture.
- the melted mass is passed the through an injector into the preformed cavities followed by cooling and blister packaging.
- a soft pastille in accordance with the present invention was prepared with the following composition.
- Each pastille (1500mg) contains:
- Each pastille (1500mg) contains:
- Nicotine from Nicotine poliacrilex (Img 5mg) : 5 mg
- Each pastille (1500mg) contains:
- Nicotine from Nicotine poliacrilex (Img 5mg) : 5 mg
- Nicotine Polacrilex contain 20 % Nicotine; 1 mg of Nicotine Polacrilex Nicotine]
- Each of the 10 subjects was instructed to hold and suck the pastille of the present invention.
- the time required to completely dissolve the pastille in the mouth was recorded by each of the subjects.
- Nicotine craving depends upon daily stress patterns, sleep and eating habits, body weight, previous smoking levels and the like.
- the desire or need for pastilles typically will vary during any given day and from day to day, as well as from patient to patient.
- nicotine withdrawal symptoms specified by the DSM-III-R, are scored based on the following symptoms: nicotine craving, irritability, frustration, anger, anxiety, difficulty concentrating, and restlessness. Severity of each symptom is rated as (0) none, (1) slight, (2) mild, (3) moderate, or (4) severe. A mean combined withdrawal symptom score is calculated for each patient as the average of the individual symptom scores.
- nicotine craving scale as taught in DSM-III-R, has been employed for assessment of craving of the subjects.
- a subject is asked to rate his craving for nicotine, as well as his level of irritability, frustration, anger, anxiety, difficulty in concentrating and restlessness. Severity of each symptom is then rated on a scale between 0 and 4, wherein 0 is none; 1 is slight; 2 is mild; 3 is moderate; and 4 is severe.
- the mean combined withdrawal symptom score is calculated for the subject as the average of all of the symptom scores.
- Group A 10 subjects who received nicotine soft gelatin pastille [Pastille containing 2 mg of nicotine] and Group B: 10 subjects who received placebo.
- Group B 10 subjects who received placebo
- Group I 5 subjects were administered the pastilles [pastille containing 2 mg of nicotine] of the present invention while subjects of Group II were administered nicotine lozenges.
- the observations are provided in Table 9 & 10 given below:
- Group I 5 subjects were administered the pastilles [pastille containing 4 mg of nicotine] of the present invention while Group II were administered nicotine lozenges.
- the subjects were encouraged to substitute smoking/ tobacco chewing by pastille consumption; in the second phase (i. e. once the subject has switched to pastille consumption without the need for smoking) the subjects were encouraged to taper down the frequency of pastille consumption for attaining the ultimate goal of successful quitting.
- the duration of the first phase and the second phase was varied from subject to subject depending on the response shown by the subject.
- a subject is said to have successfully quit smoking in this context when he/she no longer smokes or consumes nicotine through any other means which also include the pastilles of the present invention.
- Phase 1 out of the 5 subjects, 2 could completely switch to the Phase 2 (Pastille only).
- the frequency of 2 of the subjects who switched to Phase 2 was 10 pastilles (2mg) per day as reported on the last day of the study period.
- the two subjects who could not switch to phase2 of the study reported reduction in frequency of tobacco chewing to just 2 times a day along with pastille consumption frequency of 2 pastilles (2mg) per day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080064198.XA CN102770138B (en) | 2010-02-18 | 2010-11-26 | Soft gel lozenge containing nicotine |
EP20100846028 EP2536409A4 (en) | 2010-02-18 | 2010-11-26 | Nicotine-containing soft gelatin pastilles |
KR1020127021803A KR20130008535A (en) | 2010-02-18 | 2010-11-26 | Nicotine-containing soft gelatin pastilles |
UAA201209968A UA107103C2 (en) | 2010-02-18 | 2010-11-26 | Soft gelatin nicotine-containing pastille |
MX2012009586A MX2012009586A (en) | 2010-02-18 | 2010-11-26 | Nicotine-containing soft gelatin pastilles. |
BR112012020731A BR112012020731A2 (en) | 2010-02-18 | 2010-11-26 | soft gelatin tablets with nicotine. |
JP2012553443A JP5845194B2 (en) | 2010-02-18 | 2010-11-26 | Nicotine-containing soft gelatin troche |
ZA2012/06597A ZA201206597B (en) | 2010-02-18 | 2012-08-30 | Nicotine-containing soft gelatin pastilles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN452/MUM/2010 | 2010-02-18 | ||
IN452MU2010 | 2010-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011101860A1 true WO2011101860A1 (en) | 2011-08-25 |
Family
ID=43531759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2010/000768 WO2011101860A1 (en) | 2010-02-18 | 2010-11-26 | Nicotine-containing soft gelatin pastilles |
Country Status (18)
Country | Link |
---|---|
US (1) | US8470366B2 (en) |
EP (1) | EP2536409A4 (en) |
JP (1) | JP5845194B2 (en) |
KR (1) | KR20130008535A (en) |
CN (1) | CN102770138B (en) |
AU (1) | AU2011100027A4 (en) |
BR (1) | BR112012020731A2 (en) |
CH (1) | CH702775B1 (en) |
CL (1) | CL2012002115A1 (en) |
CO (1) | CO6511280A2 (en) |
CR (1) | CR20120400A (en) |
DO (1) | DOP2012000217A (en) |
EA (1) | EA018939B1 (en) |
MX (1) | MX2012009586A (en) |
MY (1) | MY153805A (en) |
UA (1) | UA107103C2 (en) |
WO (1) | WO2011101860A1 (en) |
ZA (1) | ZA201206597B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3117826A4 (en) * | 2014-03-11 | 2017-09-13 | Farmalider, S.A. | Tobacco substitute product |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130078307A1 (en) * | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
WO2015009913A1 (en) | 2013-07-19 | 2015-01-22 | Altria Client Services Inc. | Methods and systems for incorporating nicotine into oral products |
RU2675231C2 (en) * | 2013-08-08 | 2018-12-18 | Орахэлс Корп. | Reducing reflux while sleeping by stimulating saliva with adhering troches |
US9351936B2 (en) * | 2013-10-03 | 2016-05-31 | Altria Client Services Llc | Nicotine lozenge |
US10105320B2 (en) | 2013-10-03 | 2018-10-23 | Altria Client Services | Soluble fiber lozenge |
US11779045B2 (en) | 2013-10-03 | 2023-10-10 | Altria Client Services Llc | Dissolvable-chewable exhausted-tobacco tablet |
US10244786B2 (en) | 2013-10-03 | 2019-04-02 | Altria Client Services Llc | Tobacco lozenge |
US9999243B2 (en) | 2013-10-03 | 2018-06-19 | Altria Client Services Llc | Exhausted tobacco lozenge |
IN2013MU01590A (en) * | 2013-11-02 | 2015-08-07 | Jatin Vasant Thakkar | |
US9375033B2 (en) * | 2014-02-14 | 2016-06-28 | R.J. Reynolds Tobacco Company | Tobacco-containing gel composition |
KR20240052071A (en) * | 2016-07-29 | 2024-04-22 | 필립모리스 프로덕츠 에스.에이. | Aerosol-generating system comprising a heated gel container |
US10772355B2 (en) | 2016-07-29 | 2020-09-15 | Altria Client Services Llc | Aerosol-generating system including a heated gel container |
WO2023062109A1 (en) | 2021-10-13 | 2023-04-20 | Wm19 Holding Ag | Oral formulations comprising nicotine salt |
KR20240048898A (en) | 2022-10-07 | 2024-04-16 | 어보브반도체 주식회사 | Syncronous rectifier type dc-dc converter |
WO2024037043A1 (en) * | 2023-04-28 | 2024-02-22 | 深圳华宝协同创新技术研究院有限公司 | Nicotine-containing film composition for oral mucosa |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US680734A (en) | 1900-09-13 | 1901-08-20 | N L Syndicate Ltd | Process of making waterproof fabric and product thereof. |
GB2230439A (en) | 1989-04-20 | 1990-10-24 | Alec Stanley Walter Shaw | Nicotine lozenges |
US4967773A (en) | 1986-06-26 | 1990-11-06 | Shaw Alec S W | Nicotine containing lozenge |
WO1991006288A1 (en) * | 1989-11-07 | 1991-05-16 | Anders Dam | A nicotine containing stimulant unit |
WO1995003050A2 (en) * | 1993-07-26 | 1995-02-02 | Pharmetrix Corporation | Improved nicotine lozenge and therapeutic method for smoking cessation |
US5488962A (en) | 1990-10-10 | 1996-02-06 | Perfetti, S.P.A. | Chewing gum which is a substitute for tobacco smoke |
GB2299756A (en) | 1995-03-29 | 1996-10-16 | Gilbert Falkingham Clayton | Gelatinous pastille containing nicotine |
US6183775B1 (en) | 1996-05-13 | 2001-02-06 | Novartis Consumer Health S.A. | Buccal delivery system |
US6344222B1 (en) | 1998-09-03 | 2002-02-05 | Jsr Llc | Medicated chewing gum delivery system for nicotine |
WO2002076211A1 (en) * | 2001-03-26 | 2002-10-03 | Smithkline Beecham Corporation | Nicotine-containing oral dosage form |
US20040151771A1 (en) | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
WO2007133140A1 (en) | 2006-05-16 | 2007-11-22 | Mcneil Ab | Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525351A (en) * | 1989-11-07 | 1996-06-11 | Dam; Anders | Nicotine containing stimulant unit |
US5928664A (en) * | 1998-02-11 | 1999-07-27 | Fuisz Technologies Ltd. | Consumable gummy delivery system |
US20030087937A1 (en) * | 2001-10-15 | 2003-05-08 | Nils-Olof Lindberg | Nicotine and cocoa powder compositions |
CN1761458A (en) * | 2003-05-02 | 2006-04-19 | 沃尼尔·朗伯有限责任公司 | Confectionery products for delivery of pharmaceutically active agents to the throat |
WO2005018348A2 (en) * | 2003-08-11 | 2005-03-03 | William Whalen | Chewing tobacco substitute with nicotine |
ES2321721T3 (en) * | 2003-09-08 | 2009-06-10 | Mcneil Ab | NICOTINE FORMULATIONS AND USE OF THE SAME. |
US20050123502A1 (en) * | 2003-10-07 | 2005-06-09 | Chan Shing Y. | Nicotine containing oral compositions |
CN101404978B (en) * | 2006-02-24 | 2013-06-26 | 路博润高级材料公司 | Polymers containing silicone copolyol macromers and personal care compositions containing same |
CA2657932A1 (en) * | 2006-03-16 | 2007-09-20 | Niconovum Ab | Stable lozenge compositions providing rapid release of nicotine |
US20070269492A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
CL2009001025A1 (en) | 2008-05-01 | 2010-09-24 | Smithkline Beecham Corp | Lozenge composition comprising: a) a standard granule with at least: an alkaline buffering agent, a dissolution modifier and a filler, b) a defined extragranular nicotine active ingredient and at least one alkaline buffering agent; preparation procedure; Useful to eliminate or reduce tobacco use. |
-
2010
- 2010-11-26 CN CN201080064198.XA patent/CN102770138B/en not_active Expired - Fee Related
- 2010-11-26 WO PCT/IN2010/000768 patent/WO2011101860A1/en active Application Filing
- 2010-11-26 BR BR112012020731A patent/BR112012020731A2/en not_active IP Right Cessation
- 2010-11-26 KR KR1020127021803A patent/KR20130008535A/en not_active Application Discontinuation
- 2010-11-26 UA UAA201209968A patent/UA107103C2/en unknown
- 2010-11-26 JP JP2012553443A patent/JP5845194B2/en not_active Expired - Fee Related
- 2010-11-26 EP EP20100846028 patent/EP2536409A4/en not_active Withdrawn
- 2010-11-26 MX MX2012009586A patent/MX2012009586A/en not_active Application Discontinuation
-
2011
- 2011-01-06 AU AU2011100027A patent/AU2011100027A4/en not_active Ceased
- 2011-02-07 EA EA201100153A patent/EA018939B1/en not_active IP Right Cessation
- 2011-02-08 CH CH00229/11A patent/CH702775B1/en not_active IP Right Cessation
- 2011-02-17 US US13/029,163 patent/US8470366B2/en active Active
- 2011-02-18 MY MYPI2011000742A patent/MY153805A/en unknown
-
2012
- 2012-07-27 CR CR20120400A patent/CR20120400A/en unknown
- 2012-07-31 CL CL2012002115A patent/CL2012002115A1/en unknown
- 2012-08-06 DO DO2012000217A patent/DOP2012000217A/en unknown
- 2012-08-08 CO CO12132681A patent/CO6511280A2/en not_active Application Discontinuation
- 2012-08-30 ZA ZA2012/06597A patent/ZA201206597B/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US680734A (en) | 1900-09-13 | 1901-08-20 | N L Syndicate Ltd | Process of making waterproof fabric and product thereof. |
US4967773A (en) | 1986-06-26 | 1990-11-06 | Shaw Alec S W | Nicotine containing lozenge |
GB2230439A (en) | 1989-04-20 | 1990-10-24 | Alec Stanley Walter Shaw | Nicotine lozenges |
WO1991006288A1 (en) * | 1989-11-07 | 1991-05-16 | Anders Dam | A nicotine containing stimulant unit |
US5488962A (en) | 1990-10-10 | 1996-02-06 | Perfetti, S.P.A. | Chewing gum which is a substitute for tobacco smoke |
WO1995003050A2 (en) * | 1993-07-26 | 1995-02-02 | Pharmetrix Corporation | Improved nicotine lozenge and therapeutic method for smoking cessation |
GB2299756A (en) | 1995-03-29 | 1996-10-16 | Gilbert Falkingham Clayton | Gelatinous pastille containing nicotine |
US6183775B1 (en) | 1996-05-13 | 2001-02-06 | Novartis Consumer Health S.A. | Buccal delivery system |
US6344222B1 (en) | 1998-09-03 | 2002-02-05 | Jsr Llc | Medicated chewing gum delivery system for nicotine |
WO2002076211A1 (en) * | 2001-03-26 | 2002-10-03 | Smithkline Beecham Corporation | Nicotine-containing oral dosage form |
US20040151771A1 (en) | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
WO2007133140A1 (en) | 2006-05-16 | 2007-11-22 | Mcneil Ab | Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
Non-Patent Citations (1)
Title |
---|
See also references of EP2536409A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3117826A4 (en) * | 2014-03-11 | 2017-09-13 | Farmalider, S.A. | Tobacco substitute product |
Also Published As
Publication number | Publication date |
---|---|
CN102770138B (en) | 2015-12-09 |
JP2013520408A (en) | 2013-06-06 |
CR20120400A (en) | 2012-10-23 |
CO6511280A2 (en) | 2012-08-31 |
US8470366B2 (en) | 2013-06-25 |
CN102770138A (en) | 2012-11-07 |
EA201100153A1 (en) | 2011-08-30 |
MX2012009586A (en) | 2012-09-12 |
MY153805A (en) | 2015-03-31 |
KR20130008535A (en) | 2013-01-22 |
EP2536409A1 (en) | 2012-12-26 |
JP5845194B2 (en) | 2016-01-20 |
BR112012020731A2 (en) | 2016-04-26 |
US20110200670A1 (en) | 2011-08-18 |
ZA201206597B (en) | 2013-05-29 |
CH702775B1 (en) | 2011-08-15 |
EA018939B1 (en) | 2013-11-29 |
AU2011100027A4 (en) | 2011-02-03 |
UA107103C2 (en) | 2014-11-25 |
DOP2012000217A (en) | 2013-03-15 |
EP2536409A4 (en) | 2013-07-17 |
CL2012002115A1 (en) | 2013-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011100027A4 (en) | Nicotine containing soft gelatin pastilles | |
JP5710121B2 (en) | Medicinal products for intraoral delivery of nicotine containing trometamol as a buffering agent | |
AU2008251095B2 (en) | Oral nicotine formulation buffered with amino acid | |
JP2012505878A (en) | Multiple partial oral dosage forms and uses thereof | |
ZA201002188B (en) | Multi-portion intra-oral dosage form with organoleptic properties | |
BRPI0712068A2 (en) | coated pharmaceutical product for intraoral nicotine delivery comprising trometamol as a buffering agent | |
PT2186507E (en) | A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity | |
US20170007594A1 (en) | Therapeutic composition and configuration | |
RU2282447C2 (en) | Nicotine-containing pharmaceutical composition and its using | |
AU2002334523A1 (en) | New formulations and use thereof | |
Chauhan et al. | Nicotine replacement therapy for smoking cessation | |
WO2015068058A1 (en) | Tobacco free 'niconuts'and the process thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080064198.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10846028 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12012501487 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2012-000400 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012553443 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12132681 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 221484 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201209968 Country of ref document: UA Ref document number: MX/A/2012/009586 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127021803 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010846028 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012020731 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012020731 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120817 |